What is LOPJLB’s current signal on NGNE?

LOPJLB’s latest quantitative signal on Neurogene Inc. (NGNE) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is NGNE in?

Neurogene Inc. (NGNE) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does Neurogene Inc. (NGNE) do?

Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype…

Where is Neurogene Inc. based / listed?

Neurogene Inc. is based in US, listed on NASDAQ.

Neurogene Inc. (NGNE)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$26.40-0.38%Close

SELLCRISIS · day 19

RANGE

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONEBEST

Key stats

Short interest · FINRA settlement 2026-09-30

Market cap: $417M
Beta: 1.96
P/E (TTM): -4.62

Short % float: 39.68%
Days to cover: 11.7
SI change: +51.7%

1W: +2.92%
1M: -26.91%

vs SPY 1W: +1.37%
vs SPY 1M: -28.67%

Industry peers

FMP comparable companies · ranked by market cap

TSHASELLTaysha Gene Therapies, Inc.$1.4BCRISISQ 1$4.39+1.35%
MGTXSELLMeiraGTx Holdings plc$982MCRISISQ 6$10.60+1.81%
DSGNSELLDesign Therapeutics, Inc.$748MCRISISQ -13$11.97+1.39%
FDMTSELL4D Molecular Therapeutics, Inc.$657MCRISISQ 4$12.56+4.96%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Key stats

Industry peers

Prediction markets

Company news